MS and Demyelinating Disorders

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed important behind the scenes work nurses carry out in neurology care.

A literature review suggests ferritin may serve as a “dual-edged” biomarker in multiple sclerosis, with elevated levels associated with disease progression and low levels linked to impaired remyelination.

A retrospective study presented at CMSC 2026 found GLP-1 receptor agonist use in multiple sclerosis was associated with higher physical activity levels and improvements across several patient-reported symptom domains.

Three-year extension data presented at CMSC 2026 showed sustained suppression of MRI activity and low relapse rates with frexalimab in relapsing multiple sclerosis.

A new analysis presented at CMSC 2026 suggests that rescue treatment with complement inhibition may help stabilize disease activity in Hispanic patients with NMOSD who experienced relapse despite treatment.

A real-world study presented at CMSC 2026 reported year-1 improvements in treatment satisfaction and disease impact measures in patients with MS treated with ublituximab.

An analysis from the phase 3b ENLIGHTEN study presented at the 2026 CMSC Annual Meeting showed that cognitive performance remained stable during long-term treatment with ozanimod in patients with relapsing multiple sclerosis.

Nurses Jeffrey Hernandez, DNP, APRN, and Bonnie Blain, RN, discussed the unique role of nurses in neurology, from their perspective working with patients with MS.

FACT, an ongoing trial, evaluates the efficacy of efgartigimod alfa injection versus high-dose intravenous methylprednisolone in a cohort patients with neuromyelitis optica spectrum disorder.

Here's some of what is coming soon to NeurologyLive® this week.

New findings showed that treatment with ofatumumab lowered relapse risk compared with rituximab in patients with myelin oligodendrocyte glycoprotein antibody-associated disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 22, 2026.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

The registered nurse at the University of Miami and the president of the IOMSN shared their thoughts on the unique demands of nursing in neurology, with a particular focus on their experience in multiple sclerosis nursing. [WATCH TIME: 6 minutes]

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

William Kilgo, MD, and rising chief resident Ashley Nguyen, MD, discuss the evolving neurology residency Match process, offering guidance on competitiveness, interviews, program fit, and recruitment in the virtual era.

Here's some of what is coming soon to NeurologyLive® this week.

The FDA approval of ocrelizumab for pediatric RRMS expands access to a high-efficacy anti-CD20 therapy for children and adolescents with historically limited treatment options.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Neurologist Michael Levy, MD, PhD, outlines phase 3 METEOROID findings demonstrating satralizumab’s ability to reduce relapse risk and provide early, sustained disease control in patients with MOGAD.

Neurology News Network for the week ending May 2nd, 2026. [WATCH TIME: 5 minutes]

Machine learning will only transform clinical neurology if predictive accuracy is matched by usability, transparency, and active physician involvement in the design and implementation of tools that support patient care.

CHMP has recommended tolebrutinib for nonrelapsing SPMS following phase 3 data showing reduced disability progression, supporting its role in targeting CNS-driven inflammation.